- Home
- CNF vs RNXT Comparison
CNF vs RNXT Comparison
Compare CNF & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNF | RNXT |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.7M | 36.4M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNF | RNXT |
|---|---|---|
| Price | $5.98 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 10.5K | ★ 295.1K |
| Earning Date | 08-28-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,241,013.00 | $928,000.00 |
| Revenue This Year | $252.34 | $2,795.35 |
| Revenue Next Year | N/A | $272.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.36 | $0.70 |
| 52 Week High | $13.90 | $1.69 |
Technical Indicators
Market Signals| Indicator | CNF | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 51.11 |
| Support Level | $5.60 | $0.92 |
| Resistance Level | $6.10 | $0.93 |
| Average True Range (ATR) | 0.27 | 0.06 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 90.00 | 76.75 |
Price Performance
Historical ComparisonAbout CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.